Indaptus Therapeutics, Inc.

NASDAQ:INDP

Biotechnology

Healthcare
$3.29 -2.21%

-$0.03 today

Market cap
$372.57M
Beta
1.14
P/E (TTM)
-0.2
EPS (TTM)
-$8.70
52W Low $0.92High $8.69

Volume 0.17M

Average 0.97M

INDP Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Indaptus Therapeutics, Inc.NASDAQ: INDP

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$83.83M, compared with -$64.97M a year earlier.

Context

  • Retained earnings amounted to 3843.9% of total assets at the end of Q1 FY2026, up 2643.3 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -29.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$83.83M-3.1% QoQ
Last fiscal yearDec 2025
-$81.29M-34.5% YoY
Year agoMar 2025
-$64.97M-29.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.0%——
1 year-34.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(81.29M) USD
Year-over-year change
-34.5%

Retained Earnings vs competitors

How INDP compares with its peers on the latest reported figures

  • INDP's Mar 2026 retained earnings of -$83.83M is the lowest of the 2 companies compared; the peer median is -$75.8M.
  • Its year-over-year change of -29.0% is the lowest of 2, against a peer median of -19.3%.
  • Retained earnings amounts to 3843.9% of total assets for INDP, versus a peer median of 850.1%.
INDP Competitors Peer median
Retained Earnings for INDP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AZTRAzitra, Inc.Jun 2026-$75.8M -19.3%—850.1%
INDPIndaptus Therapeutics, Inc.Mar 2026-$83.83M -29.0%—3843.9%
Peer median (excluding INDP) -$75.8M-19.3%—850.1%

Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents39.13M9.63M13.36M5.79M8.51M
Short-term Investments016.81M000
Net Receivables21.06K0000
Inventory00000
Other Current Assets148.4K0000
Total Current Assets40.39M27.24M14M6.62M9.31M
Property, Plant & Equipment (Net)172.89K81.31K173.94K82.18K0
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets16.48K738.25K754.73K638.25K0
Total Non-current Assets189.37K819.56K928.67K720.43K0
Total Assets40.58M28.06M14.92M7.34M9.31M
Account Payables2.64M1.38M806K870.23K544.06K
Short-term Debt00000
Tax Payables0128.93K40K00
Deferred Revenue00000
Other Current Liabilities498.73K1.22M1.21M1.37M4.03M
Total Current Liabilities4.6M3.43M2.77M3.39M6.16M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities72.86K073.35K00
Total Liabilities4.68M3.43M2.85M3.39M6.16M
Common Stock82.59K84.01K84.01K120.14K21.67K
Retained Earnings(15.67M)(29.99M)(45.42M)(60.44M)(81.29M)
Accumulated OCI096.43K000
Other Stockholders Equity00000
Minority Interest00000
Total Equity35.9M24.63M12.08M3.94M3.15M
Total Debt169.33K80.49K175.05K84.16K0
Net Debt(38.96M)(9.55M)(13.19M)(5.7M)(8.51M)

Indaptus Therapeutics, Inc.

NASDAQ:INDP

Intrinsic Alpha fair value

Locked

Current Price

$3.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.